Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine diagnostic screening and detection tests for colorectal cancer and other common tumors to a simple blood draw. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialize the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in diseases development. The company was founded in 2012 and is headquartered in Cambridge, UK.